Endomorphin-1

Endomorphin-1 (EM-1) is a naturally occurring tetrapeptide first identified and characterized in 1997 by James Zadina, Abba Kastin, and colleagues, published in a landmark paper in Nature (PMID 9087409). It was isolated as one of two closely related endogenous peptides (alongside endomorphin-2) representing, at the time of discovery, the most selective endogenous ligands ever identified for the mu-opioid receptor — the same receptor targeted by morphine and most clinically used opioid analgesics.

Chemically, Endomorphin-1 has the sequence Tyr-Pro-Trp-Phe with a C-terminal amide group (Tyr-Pro-Trp-Phe-NH2), molecular formula C34H38N6O5, molecular weight approximately 610.7 g/mol (calculated from the formula), CAS number 189388-22-5, PubChem CID 5311080. At Verified Peptides, we think its extraordinarily high mu-receptor binding affinity (reported dissociation constant around 360 picomolar) combined with its unusually strong selectivity (roughly 4,000-fold over the delta opioid receptor and 15,000-fold over the kappa opioid receptor) makes it one of the most receptor-selective peptides in this entire catalog.

Despite this exceptional pharmacological selectivity, no endomorphin-based drug has reached clinical development or approval. This is not because the underlying receptor pharmacology is in question — it is well replicated — but because of specific, well-documented pharmacokinetic limitations described in the research summary below.

Endomorphin-1 belongs to a broader family of endogenous opioid peptides that includes the enkephalins, dynorphins, and beta-endorphin, all of which activate one or more of the three classical opioid receptors (mu, delta, and kappa) with varying degrees of selectivity. What sets Endomorphin-1 and its close relative Endomorphin-2 apart from this broader family is the unusual degree of mu-receptor selectivity they display — most other endogenous opioid peptides show meaningfully overlapping activity across multiple opioid receptor subtypes, whereas Endomorphin-1's selectivity profile is unusually clean, making it a particularly useful pharmacological tool for isolating mu-receptor-specific effects from the broader opioid receptor family's overlapping biology.

At Verified Peptides, we think Endomorphin-1's research history illustrates a specific, common pattern in peptide pharmacology: a genuinely excellent, well-replicated receptor-pharmacology finding that has not translated into a marketed drug due to pharmacokinetic rather than pharmacodynamic limitations. The foundational discovery paper (Zadina et al., Nature, 1997, PMID 9087409) established Endomorphin-1's existence and its remarkable mu-opioid receptor selectivity, a finding that has been extensively replicated and built upon across the opioid pharmacology field in the nearly three decades since.

Recognizing that the native peptide's poor plasma stability and blood-brain barrier penetration were the primary barriers to therapeutic development, substantial subsequent research has focused on chemically modified Endomorphin-1 analogs designed to overcome these specific limitations while retaining its receptor selectivity. A 2007 study (PMID 17188879) described endomorphin-1 analogs engineered for enhanced metabolic stability and demonstrated systemic analgesic activity, directly addressing the native peptide's stability limitation. Separate research programs have explored glycosylated and lipidated Endomorphin-1 derivatives specifically designed to improve blood-brain barrier penetration, including cyclic glycopeptide analogs assessed via microdialysis and mass spectrometry for actual brain penetration, and lipo-endomorphin derivatives studied for systemic activity against neuropathic pain notably without producing the constipation commonly associated with conventional opioid analgesics — a specific, clinically meaningful side-effect difference from morphine-class drugs that has kept research interest in this peptide family active.

We want to be direct about where this leaves native Endomorphin-1 itself: despite nearly 30 years of active research interest and multiple generations of engineered analogs designed to translate its receptor pharmacology into a viable drug, no Endomorphin-1-based therapy — either the native peptide or an engineered analog — has reached FDA approval or, to our knowledge, advanced through completed human clinical trials. This makes Endomorphin-1 a compound with excellent, well-established basic pharmacology but no successful clinical translation to date, a genuinely different evidentiary situation from compounds in this catalog with either strong clinical data or essentially no research at all.

At Verified Peptides, we sell research-grade Endomorphin-1 exclusively for laboratory research. We think it remains one of the most scientifically important reference compounds in opioid receptor pharmacology, valuable for mu-opioid receptor selectivity and desensitization research specifically, even without a corresponding clinical drug development success story.

Endomorphin-1 and Endomorphin-2 (a closely related but distinct tetrapeptide, Tyr-Pro-Phe-Phe-NH2) were both identified in the same 1997 discovery work and are frequently discussed together, but researchers should note they are separate compounds with subtly different receptor-binding characteristics and, in some studies, different regional distribution patterns within the central nervous system — Endomorphin-1 is more concentrated in certain brainstem and diencephalic regions, while Endomorphin-2 shows a distinct distribution pattern, suggesting the two peptides may serve at least partially non-redundant physiological roles despite their close structural and functional similarity.

A notable and clinically relevant research thread involves Endomorphin-1 analogs specifically designed to avoid producing constipation, one of the most common and clinically troublesome side effects of conventional opioid analgesics (caused by mu-opioid receptor activity in the gastrointestinal tract). Lipidated Endomorphin-1 derivatives studied for neuropathic pain have reportedly achieved systemic analgesic activity without this specific side effect in preclinical models, representing a genuinely distinct potential clinical advantage over existing opioid drugs if such an analog were ever to reach clinical development.

The precise biosynthetic origin of endomorphins remains, notably, less definitively established than for many other endogenous peptides in this catalog: unlike classical opioid peptides such as the enkephalins, dynorphins, and beta-endorphin (all cleaved from well-characterized precursor proteins — proenkephalin, prodynorphin, and proopiomelanocortin respectively), a definitive proendomorphin precursor gene has been more difficult to conclusively identify, and this remains an area of ongoing investigation nearly three decades after the peptides' initial discovery.

Endomorphin-1's reported lack of significant receptor desensitization upon repeated administration, if it holds up under further research and could be translated into a stable, brain-penetrant drug candidate, would represent a potentially significant advantage over morphine-class opioids, for which tolerance (requiring escalating doses for the same effect) is a major clinical limitation — this remains one of the most scientifically compelling, if clinically unrealized, aspects of Endomorphin-1's research profile.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Endomorphin-1 we offer, with a Certificate of Analysis (COA) available for each lot. As a four-residue amidated peptide, Endomorphin-1 can be synthesized to high purity using standard solid-phase peptide synthesis methods, with the C-terminal amidation requiring specific synthesis chemistry appropriate to that modification.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage, correct C-terminal amidation, and molecular identity before use in any experimental protocol.

Lyophilized Endomorphin-1 is stable when stored at -20°C, protected from light and moisture, and researchers can generally expect the unreconstituted peptide to maintain integrity over an extended period under these conditions. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted, Endomorphin-1 solution should be stored refrigerated at 2–8°C and used promptly, given the compound's well-documented susceptibility to rapid degradation by peptidases in biological samples — the same pharmacokinetic limitation relevant to its research and clinical development history is also directly relevant to in vitro experimental handling.

Researchers should avoid repeated freeze-thaw cycles of reconstituted material and should follow the specific storage guidance provided with each lot's documentation, with particular attention to using freshly reconstituted material promptly in any experimental protocol given this peptide's inherent instability.